Hemogenyx Pharmaceuticals Plc (HOPHF)
USD 1.24
(0.0%)
USD 1.24
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 645.68 Thousand | 2.59 Million | 283.64 Thousand | 350.71 Thousand | 421.81 Thousand | 348.26 Thousand |
| Gross Profit | -645.68 Thousand | -2.59 Million | -283.64 Thousand | -350.71 Thousand | -421.81 Thousand | -348.26 Thousand |
| Operating Expenses | 6.46 Million | 2.93 Million | 2.54 Million | 1.86 Million | 1.24 Million | 1.26 Million |
| Selling, General and Administrative Expenses | 4.91 Million | 942.35 Thousand | 1.39 Million | 628.06 Thousand | 462.57 Thousand | 417.61 Thousand |
| Research and Development Expenses | 90.63 Thousand | 487.10 | 50.82 | 114.41 | 28.14 | 73.50 |
| Other Expenses | 1.46 Million | - | - | 85.23 Thousand | 213.12 Thousand | 91.35 Thousand |
| Cost and Expenses | 6.46 Million | 5.53 Million | 2.83 Million | 2.21 Million | 1.67 Million | 1.6 Million |
| Operating Income | -6.46 Million | 3.99 Million | -2.7 Million | -2.15 Million | -1.68 Million | -1.61 Million |
| Interest Expense | 315.99 Thousand | 33.00 | 2.59 Million | 33.23 Thousand | 31.32 Thousand | 1779.00 |
| Income Tax Expense | - | 361.2 Thousand | 2.41 Million | 20.51 Thousand | -35 Thousand | -43.75 Thousand |
| Earnings before Tax | -6.69 Million | -3.98 Million | -5.1 Million | -2.09 Million | -1.48 Million | -1.52 Million |
| Net Income | -6.69 Million | -3.97 Million | -5.09 Million | -2.08 Million | -1.45 Million | -1.47 Million |
| Earnings Per Share Basic | -0.01 | -0.00 | -0.01 | -0.01 | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.01 | -0.00 | -0.01 | -0.01 | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 1.12 Billion | 979.74 Million | 773.95 Million | 414.83 Million | 360.71 Million | 360.12 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.12 Billion | 979.74 Million | 773.95 Million | 414.83 Million | 360.71 Million | 360.12 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -5.33 Million | -5.44 Million | -2.55 Million | -2.08 Million | -1.62 Million | -1.63 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | 325.77 Thousand | 645.68 Thousand | - | 319.9 Thousand |
| Gross Profit | - | - | -325.77 Thousand | -645.68 Thousand | - | -319.9 Thousand |
| Operating Expenses | 1345.57 | 1345.57 | 1124.81 | 4.91 Million | 1124.82 | 3.89 Million |
| Selling, General and Administrative Expenses | 1184.73 | 1184.73 | 508.28 | - | 508.28 | 3.89 Million |
| Research and Development Expenses | - | - | 45.32 | - | 45.32 | - |
| Other Expenses | 160.84 | 160.84 | 571.22 | - | - | - |
| Cost and Expenses | 1345.57 | 1345.57 | 1124.81 | 5.55 Million | 1124.82 | 4.21 Million |
| Operating Income | -1345.57 | -1345.57 | -1124.81 | -5.55 Million | -671.17 | -4.21 Million |
| Interest Expense | - | - | 153.95 Thousand | 315.99 Thousand | - | 162.03 Thousand |
| Income Tax Expense | -1.39 | -1.39 | -3356.00 | -5816.00 | -1.68 | -1.56 |
| Earnings before Tax | -1407.80 | -1407.80 | -1186.47 | -6.69 Million | -1186.47 | -4.32 Million |
| Net Income | -1406.42 | -1406.42 | -1184.79 | -6.69 Million | -1184.79 | -4.32 Million |
| Earnings Per Share Basic | - | -0.00 | -0.00 | - | -0.00 | -0.00 |
| Earnings Per Share Diluted | - | -0.00 | -0.00 | - | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 1.22 Billion | 1.22 Billion | 1.21 Billion | 1.12 Billion | 1.21 Billion | 1.04 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.22 Billion | 1.22 Billion | 1.21 Billion | 1.12 Billion | 1.21 Billion | 1.04 Billion |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -1287.17 | -1287.17 | -613.35 | - | -613.35 | -3.89 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
AGI
CWB
SCHNEIDER
TAKE
6103
301606